SCHEMBL22712349

SCHEMBL22712349

CSc1nc(Cl)cc(-c2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.44
ACP1 P24666 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
ALOX5 P09917 1/20 0.41
MAPT P10636 3/20 0.40
MAPK1 P28482 2/20 0.40
RECQL P46063 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SCN10A Q9Y5Y9 3/20 0.40
SCN5A Q14524 4/20 0.40
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
LIPE Q05469 1/20 0.39
F2RL3 Q96RI0 1/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
CHRNA7 P36544 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22712307 0.82 CYP1A2 (0.42) SCN5AF2RL3GAACYP1A2
SCHEMBL7873581 0.81 KDM4E (0.49) ADORA3ALOX5MAPTL3MBTL1KDM4E
SCHEMBL22712302 0.81 KDM4E (0.46) DHODHACP1ADORA3MAPTMAPK1
SCHEMBL21058652 0.81 DHODH (0.49) DHODHACP1ADORA3ALOX5MAPT
SCHEMBL22712341 0.80 ACP1 (0.42) DHODHACP1ADORA3MAPTMAPK1
SCHEMBL4816969 0.77 NPC1 (0.39) MAPTL3MBTL1KDM4EGAANPC1
SCHEMBL7521036 0.76 KDM4E (0.56) MAPTL3MBTL1KDM4EGAANPC1
SCHEMBL22712296 0.74 ADORA3 (0.42) DHODHACP1ADORA3MAPTMAPK1
SCHEMBL3997703 0.74 AKR1C2 (0.50) DHODHALOX5MAPTMAPK1RECQL
SCHEMBL3874666 0.72 LMNA (0.54) KDM4EGAANPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773099-B2 Compounds and their methods of use PRAXIS PRECISION MEDICINES, INC. (US) 2023-10-03 US disclosed
US-11773099-B2 Compounds and their methods of use PRAXIS PRECISION MEDICINES, INC. (US) 2023-10-03 US disclosed
US-11773099-B2 Compounds and their methods of use PRAXIS PRECISION MEDICINES, INC. (US) 2023-10-03 US disclosed
US-20200377506-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2020-12-03 US disclosed
US-20200377506-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2020-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377506-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B DHODH 836/4885ACP1 3464/4885ADORA3 2285/4885
US-11773099-B2 Compounds and their methods of use SCN1A, SCN1B, SCN3A DHODH 1523/4885ACP1 3894/4885ADORA3 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.